<DOC>
	<DOCNO>NCT01148095</DOCNO>
	<brief_summary>AZD2516 develop oral treatment chronic neuropathic pain . This study split two part . Part A measure effect food new formulation drug blood see well tolerate . Part B commence completion Part A investigate safety tolerability daily dose AZD2516 .</brief_summary>
	<brief_title>To Investigate Safety , Tolerability Pharmacokinetics AZD2516 After Multiple Dosing Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Have body mass index ( BMI ) 18 30 kg/m2 weigh least 50 kg 100 kg Healthy volunteer able willing comply study requirement . An ongoing history medical psychiatric disease/condition may put healthy volunteer risk interfere study objective participation study , judge investigator ( ) . History psychotic disorder among first degree relative .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AZD2516</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>Multiple ascending dos</keyword>
</DOC>